Leukemia & Lymphoma

Acalabrutinib Plus Obinutuzumab Well-Tolerated, Effective in CLL

06/04/2019

Acalabrutinib in combination with obinutuzumab was well-tolerated and yielded high response rates in patients with treatment-naïve and relapsed/refractory CLL.

Acalabrutinib in combination...

06/04/2019

Oncology

Frontline Flumatinib Shows Comparable Safety, Superior Efficacy to Imatinib in Newly-Diagnosed CML

06/03/2019

Flumatinib showed comparable safety and superior efficacy to imatinib at various time points in the frontline treatment of patients with newly-diagnosed CML in chronic phase, according to data presented at ASCO 2019.

Flumatinib showed comparable...

06/03/2019

Oncology

Videos

Richard Furman, MD, Discusses Richter's Transformation and Emerging Therapies in CLL

11/08/2018

Dr Furman discusses disease progression with BTK inhibitor therapy, Richter's transformation, and emerging treatment options for CLL.

Dr Furman discusses disease...

11/08/2018

Oncology

Videos

Jonathon Cohen, MD, Discusses Treatment Options and Prognosis in MCL

11/08/2018

Dr Cohen discusses the available treatment options for patients with MCL, and describes methods for predicting patient response to specific therapies.

Dr Cohen discusses the available...

11/08/2018

Oncology

Therapies are Rapidly Evolving for Patients With Newly Diagnosed AML

10/17/2018

At the 2018 L&M congress, Gail Roboz, MD, discussed current therapy options for patients with newly diagnosed AML.

At the 2018 L&M congress, Gail...

10/17/2018

Oncology

MRD Testing a Crucial Component in Treatment of Patients With AML

10/17/2018

Clinicians should measure MRD in their patients with AML, because CR on its own is simply not enough, Gail J. Roboz, MD, asserted at the 2018 L&M congress.

Clinicians should measure MRD in...

10/17/2018

Oncology